



15th December, 2009.

PRESS RELEASE

IMPEDIMED APPOINTS L-DEX[®] DISTRIBUTOR FOR HONG KONG, CHINA, TAIWAN AND MACAU.

ImpediMed is very pleased to announce that it has appointed 3 Kings Holding Ltd. of Kowloon Bay, Hong Kong as a key Asian distributor for L-Dex products in Hong Kong, China, Taiwan and Macau. Key personnel at 3 Kings Holding Limited have previously held distinguished careers in the healthcare market in both Hong Kong and the People's Republic of China.

Greg Brown, CEO of ImpediMed commented, "This distributor appointment is an important step for ImpediMed in broadening our global presence, particularly in this large, emerging market. 3 Kings Holding Limited has a very good reputation and is the Medical and Health Products Division of WKK International Holdings Limited. We believe they are ideally suited to represent ImpediMed in this important fast growing market. The distribution appointment positions ImpediMed well as it continues to expand its global roll out of its medical device platform aimed initially at the cancer market, particularly the proactive management of lymphoedema post surgery." Mr Brown added

Dr.K.F.Leung, Executive Director & CEO of 3 Kings Holdings Ltd. stated that he is confident that ImpediMed's L-Dex products will greatly help patients by providing an advanced tool for clinical assessment of lymphoedema . "These L-Dex products are warmly welcomed by local medical professionals in Hong Kong," he said.

ENDS

For further information contact:

Greg Brown ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

L-Dex® is a trademark of ImpediMed Limited.

“ L-Dex® values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit www.impedimed.com.